Sidley Austin Beijing Senior Counsel Chen Yang: An Interview with PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Chen Yang, senior counsel in Sidley Austin's Beijing office, recently spoke with PharmAsia News about recent developments in China that affect the pharmaceutical and medical device industries. Yang leads the firm's China life sciences practice. For the past 10 years, she has advised international companies on their investment projects and acquisition efforts in various Chinese industries and provided regulatory advice on intellectual property, life science, employment and other issues. She has also assisted China government agencies in several U.S. litigation matters.
You may also be interested in...
China Biopharmaceutical Industry Will Grow To $17 Billion By 2015 – ResearchInChina Report
SHANGHAI - Production value of the Chinese pharmaceutical industry has grown at an annual average of 20 percent over the past decade, according to ResearchInChina's 2007-2008 China Biopharmaceutical Industry Report, issued in December. And China's biopharmaceutical industry is growing even faster than the traditional pharmaceutical industry, said the report